Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

New Automated Immunosuppressive Drug Assays from Roche

Published: Tuesday, June 25, 2013
Last Updated: Tuesday, June 25, 2013
Bookmark and Share
Roche enables immunosuppressive drug assays to be consolidated onto main laboratory automated platforms.

For the first time, certain immunosuppressive drug (ISD) assays can now be performed automatically on cobas® modular platforms, allowing laboratories to consolidate testing for a wide range of transplant testing/monitoring assays onto a single platform.

The new Roche automated assays for tacrolimus and cyclosporine will enhance therapeutic drug monitoring (TDM) of transplant recipients by providing the consistency and accuracy of an automated assay, while enhancing workflows, auditing and reporting capabilities in the laboratory.

Tacrolimus and cyclosporine are important ISDs used in the maintenance therapy of transplant recipients.

Due to the significant pharmacokinetic variability between patients for these drugs, TDM and concentration controlled dosing are used to tailor therapy for individual patients, ensuring the ideal balance between efficacy and toxicity.

It is therefore paramount that tests used to monitor transplant patient’s response to therapy exhibit high quality performance and are efficient to run.

The new Roche tacrolimus and cyclosporine assays will provide performance with the proven Elecsys electrochemiluminescence (ECL) technology for reliable and trusted results.

The tests can be performed on any of the cobas modular platforms, including the cobas® 4000 and cobas®6000 analyzer series or the high volume cobas® 8000 modular analyzer series, allowing a wide range of assays to be performed on a single analytical platform for increased laboratory efficiency.

This includes serology assays, allowing clinicians to test donors and recipients for important infectious diseases, and organ function tests to monitor the health and recovery of transplant patients.

Fully automated laboratories can also benefit from Roche pre- and post- analytical solutions for rapid and convenient sample preparation, storage and retrieval.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Roche and Isis Pharmaceuticals Form Alliance for Huntington's Disease
This alliance combines Isis' antisense expertise with Roche's scientific expertise in developing neurodegenerative therapeutics.
Wednesday, April 10, 2013
Roche’s new RTCA Cardio Instrument for Label-Free Functional Cardiomyocyte Toxicity Testing
New medium-throughput cell analyzer utilizes impedance readings to monitor cardiac beating and cellular events in real time.
Wednesday, September 29, 2010
Roche and reMYND Enter Agreement to Develop First-in-Class Disease-Modifying Treatments for Parkinson’s and Alzheimer’s Disease
Novel therapies to target unmet needs in neurodegenerative disorders.
Tuesday, September 07, 2010
RoACTEMRA: New Hope for Children with Systemic Juvenile Idiopathic Arthritis
First presentation of TENDER study demonstrates RoACTEMRA’s efficacy in this severe childhood condition with no currently licensed treatment.
Friday, June 18, 2010
Real-time Cell Analysis with Roche´s xCELLigence System for the Early Detection of Hepatic Cytotoxicity
Roche’s recent study describes a comprehensive workflow of in vitro techniques, including real-time cell analysis, biochemical assays, and gene expression analyzes.
Friday, June 11, 2010
Roche Licenses First-in-Class Treatments for Chronic Pain to Afferent Pharmaceuticals
Pappas, Third Rock, Domain and New Leaf Launch new company centered on novel pain management technology.
Thursday, December 24, 2009
FDA Grants Emergency Use Authorization to Roche’s Assay for 2009 H1N1 Influenza Virus
Roche’s RealTime ready Influenza A/H1N1 Detection Set for the 2009 H1N1 influenza virus has received emergency use authorization from the FDA.
Tuesday, November 17, 2009
Roche Joins Forces to Innovate Toxicity Testing and to Reduce Animal Experimentation
Roche’s xCELLigence helps improving the predictive value of in vitro assessments of organ toxicity and help to reduce animal testing in toxicity research.
Tuesday, May 19, 2009
Real-time and Dynamic Monitoring of Virus-mediated Cytopathogenicity with Roche’s xCELLigence System
Göttingen University study utilizes xCELLigence system from Roche Applied Science for testing of virus-mediated cytopathogenicity.
Friday, May 01, 2009
Halozyme Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Halozyme grants exclusive, global rights to Roche for use of Enhanze™ Technology with biologics directed against fourth target.
Tuesday, December 09, 2008
Roche Applied Science Introduces new xCELLigence RTCA MP Instrument
The xCELLigence RTCA MP allows high throughput online-measurement of cell activities without labeling.
Friday, December 05, 2008
Studies to Assess Risk of Exposure to Elevated Levels of EMS Confirm Clear Toxicity Threshold for DNA Damage
Studies emphasize lack of cancer risk for patients exposed to this impurity in Viracept.
Tuesday, August 05, 2008
Genetic Research Method Sheds Light on Drug Metabolism
Use of a mouse genetic analysis method may lead to a better understanding of how drugs are metabolized.
Tuesday, May 09, 2006
Scientific News
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Tension Helps Heart Cells Develop Normally in the Lab
Stanford engineers have uncovered the important role tension plays in growing heart cells out of the body.
Controlling Body Temperature in Response to 'Fight or Flight'
New research in The FASEB Journal suggests that blocking TRPV1 protein causes an increased release of noradrenaline, leading to an increase in core body temperatures.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A Fundamental Protection Mechanism Against Formalin In Mammals is Revealed
Formaldehyde, or formalin, is well known to all of us as a common chemical used in many industrial processes and also as a preservative, remarkably we also produce formaldehyde in our bodies.
Drug Used To Treat HIV Linked to Lower Bone Mass in Newborns
NIH study finds mothers’ use of tenofovir tied to lower bone mineral content in babies.
Bone Risks Linked to Genetic Variants
A large-scale genomic study uncovered novel genetic variants and led researchers to an unexpected gene that affects bone density and fracture risk.
Combo of 3 Antibiotics Can Kill Deadly Staph Infections
Three antibiotics that, individually, are not effective against a drug-resistant staph infection can kill the deadly pathogen when combined as a trio, according to new research.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos